Literature DB >> 21298501

Cerebrospinal fluid diagnostics in first-episode schizophrenia.

Laura Kranaster1, Dagmar Koethe, Carolin Hoyer, Andreas Meyer-Lindenberg, F Markus Leweke.   

Abstract

We evaluated the clinical use and the safety of cerebrospinal fluid diagnostics in 155 patients with the suspected diagnosis of first-episode schizophrenia. Five patients (3.2%) revealed pathological findings that lead to diagnostic re-evaluation and changes in clinical management. No serious adverse events occurred, but we documented 16 (10.3%) cases of mild to moderate headache or local pain at the puncture site. Our results underline the value of lumbar puncture in the clinical workup of first-episode patients with suspected schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298501     DOI: 10.1007/s00406-011-0193-7

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  10 in total

1.  Safety and acceptability of the research lumbar puncture.

Authors:  Elaine R Peskind; Robert Riekse; Joseph F Quinn; Jeffrey Kaye; Christopher M Clark; Martin R Farlow; Charles Decarli; Charles Chabal; Darcy Vavrek; Murray A Raskind; Douglas Galasko
Journal:  Alzheimer Dis Assoc Disord       Date:  2005 Oct-Dec       Impact factor: 2.703

2.  Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls.

Authors:  Daniel Martins-De-Souza; Thomas Wobrock; Inga Zerr; Andrea Schmitt; Joanna Gawinecka; Thomas Schneider-Axmann; Peter Falkai; Christoph W Turck
Journal:  World J Biol Psychiatry       Date:  2010-08       Impact factor: 4.132

3.  Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1.

Authors:  L V Jones-Brando; J L Buthod; L E Holland; R H Yolken; E F Torrey
Journal:  Schizophr Res       Date:  1997-05-03       Impact factor: 4.939

Review 4.  How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis?

Authors:  Sharon E Straus; Kevin E Thorpe; Jayna Holroyd-Leduc
Journal:  JAMA       Date:  2006-10-25       Impact factor: 56.272

5.  Is the word 'biomarker' being properly used by proteomics research in neuroscience?

Authors:  Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-14       Impact factor: 5.270

Review 6.  Structural neuroimaging in psychosis: a systematic review and economic evaluation.

Authors:  E Albon; A Tsourapas; E Frew; C Davenport; F Oyebode; S Bayliss; T Arvanitis; C Meads
Journal:  Health Technol Assess       Date:  2008-05       Impact factor: 4.014

7.  Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction.

Authors:  K Bechter; H Reiber; S Herzog; D Fuchs; H Tumani; H G Maxeiner
Journal:  J Psychiatr Res       Date:  2009-09-30       Impact factor: 4.791

8.  Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia.

Authors:  Daniel Martins-de-Souza; Wagner F Gattaz; Andrea Schmitt; Christiane Rewerts; Giuseppina Maccarrone; Emmanuel Dias-Neto; Christoph W Turck
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-01-22       Impact factor: 5.270

9.  Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis.

Authors:  Jeffrey T-J Huang; F Markus Leweke; David Oxley; Lan Wang; Nathan Harris; Dagmar Koethe; Christoph W Gerth; Brit M Nolden; Sonja Gross; Daniela Schreiber; Benjamin Reed; Sabine Bahn
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

10.  Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia.

Authors:  Elaine Holmes; Tsz M Tsang; Jeffrey T-J Huang; F Markus Leweke; Dagmar Koethe; Christoph W Gerth; Brit M Nolden; Sonja Gross; Daniela Schreiber; Jeremy K Nicholson; Sabine Bahn
Journal:  PLoS Med       Date:  2006-08       Impact factor: 11.069

  10 in total
  7 in total

1.  In vivo microRNA detection and quantitation in cerebrospinal fluid.

Authors:  Juan A Gallego; Marc L Gordon; Kierstyn Claycomb; Mahima Bhatt; Todd Lencz; Anil K Malhotra
Journal:  J Mol Neurosci       Date:  2012-03-09       Impact factor: 3.444

Review 2.  Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

Authors:  Nenad Vasic; Bernhard J Connemann; Robert C Wolf; Hayrettin Tumani; Johannes Brettschneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-16       Impact factor: 5.270

3.  Cerebrospinal Fluid Pathologies in Schizophrenia-Spectrum Disorder-A Retrospective Chart Review.

Authors:  Mattia Campana; Johanna Strauß; Susanne Münz; Tatiana Oviedo-Salcedo; Piyumi Fernando; Peter Eichhorn; Peter Falkai; Alkomiet Hasan; Elias Wagner
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

4.  From generation of biomarkers to treatment and psychosocial aspects of psychosis.

Authors:  P Falkai; H-J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-10       Impact factor: 5.270

5.  Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis.

Authors:  Sonja Orlovska-Waast; Ole Köhler-Forsberg; Sophie Wiben Brix; Merete Nordentoft; Daniel Kondziella; Jesper Krogh; Michael Eriksen Benros
Journal:  Mol Psychiatry       Date:  2018-08-16       Impact factor: 15.992

6.  Time for a change of practice: the real-world value of testing for neuronal autoantibodies in acute first-episode psychosis.

Authors:  Thomas A Pollak; Belinda R Lennox
Journal:  BJPsych Open       Date:  2018-07-16

Review 7.  The epidemiologic evidence linking autoimmune diseases and psychosis.

Authors:  Michael E Benros; William W Eaton; Preben B Mortensen
Journal:  Biol Psychiatry       Date:  2013-10-03       Impact factor: 13.382

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.